Biohaven Licenses IgG Degraders to Ono Pharma for Japan, Select Asian Markets

By Public Technologies
  • Biohaven entered an exclusive IgG degrader licensing agreement with Ono Pharma covering Japan, South Korea, Taiwan and ASEAN countries.
  • Payments include USD 80 million upfront and USD 20 million upon a milestone anticipated within a year.
  • Ono will pay royalties of approximately 20% on net sales in the licensed territory.
  • Lead candidate BHV-1300 is in Phase 3 development for Graves' disease; the agreement also covers next-generation IgG degraders.
  • All rights outside the licensed territory are retained, including in the United States, Europe and China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001935979-26-000080), on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.